SQZ APCs: Oncology

COMMERCIALIZATION RIGHTS:

SQZ-APC-HPV
HPV+ Solid Tumors

Phase 1
NCT04084951

Next Gen SQZ APC
Solid and Liquid Tumors

Pre-clinical

SQZ-APC-X
Solid Tumors

Pre-clinical

SQZ APCs: Infectious Disease

COMMERCIALIZATION RIGHTS:

SQZ-APC-HBV
Chronic Hepatitis B Virus

Pre-clinical

SQZ-APC-RRV
Rapid Response Vaccines

Pre-clinical

SQZ AACs: Oncology

COMMERCIALIZATION RIGHTS:

SQZ-AAC-HPV
HPV+ Solid Tumors

Phase 1
NCT04892043

SQZ-AAC-KRAS
KRAS mut Solid Tumors

Pre-clinical

Next Gen SQZ AAC
Solid and Liquid Tumors

Pre-clinical

SQZ TACs: Immune Tolerance

COMMERCIALIZATION RIGHTS:

SQZ-TAC-CeD
Celiac Disease

Pre-clinical

SQZ-TAC-T1D
Type 1 Diabetes

Pre-clinical

SQZ TAC-X
Multiple Diseases

Pre-clinical

The JDRF T1D Fund has invested in SQZ Biotech on multiple occasions to help progress the T1D program.